Integrated Pharmaceutical Executive S&OP Meeting
January 8, 2009, 2008
Action Items and Notes

Attendees: David Silver, Herb Neumann, Eldon Henson, Ralph Heasley, Bence Boelcskevy, Eric Evans, JoAnne levy, Rod Novak, Rick Hoyt, Kay Yoder, David Cano, Mike Gunning, Bill Wickenhauser, Chuck Bramlage, Steve Kriegh, Melissa Bradford-Klug

New Action Items:

Item	Responsible	Due Date
Set up meeting to define the fill rate metric for the Specialty Pharma / Generics business that accounts for the impact of quota.	Levy	Next Cycle
Determine the impact on Hobart backorder recovery if they are allocated the 300KG of Oxycodone now scheduled for Endo or any of the remaining 400KG currently forecasted for 3rd party sales.	Johnson	ASAP

Notes:

Metrics: JoAnne proposed a lower than 85% Fill Rate Metric for the Specialty Pharma/ Generics business due to the continuing issues with quota that will prevent us from hitting that level. Instead of lowering the target, Chuck requested that we re-look at ways to quantify the quota impact and keep a high level of service as our target. (Action Item)

Oxycodone:
Additional information is required to determine the final allocation of API to either Hobart or 3rd parties. We need to determine the incremental benefit of using the Endo (300kgs) or 3rd Party forecast (400kgs) to Hobart's Backorder Recovery Plan.

Specialty Pharma / Generics:
Fluid Bed Dryer Update: The January planning cycle will use the updated forecast for Tussicaps as well as the 5/4mg launch quantities to revise the long term plan for the Fluid Bed Dryer and the impact on planning Oxy IR production.

APAP Supply Chain:
Based on our current production and demand, we are already seeing some build of PAP inventory. We have set February as the planning cycle to make a supply commitment to Marketing. Outside storage is a valid option if PAP can be sold at a profit. We should start looking at the options during the January cycle.

